ETD 001
Alternative Names: ETD-001Latest Information Update: 02 Feb 2024
At a glance
- Originator Enterprise Therapeutics
- Class Antiasthmatics; Antifibrotics
- Mechanism of Action Epithelial sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis
Most Recent Events
- 30 Jan 2024 Enterprise Therapeutics plans a phase IIa trial for Cystic fibrosis (Inhalation)
- 04 Sep 2022 Safety and pharmacokinetics data from a phase I trial in Cystic fibrosis (In volunteers) presented at the 32nd Annual Congress of the European Respiratory Society (ERS-2022)
- 22 Mar 2022 Enterprise Therapeutics completes a phase I trial in Cystic fibrosis (In volunteers) in United Kingdom (Inhalation) (NCT04926701)